{
    "clinical_study": {
        "@rank": "153029", 
        "acronym": "TRANSEURO", 
        "arm_group": [
            {
                "arm_group_label": "Transplant", 
                "arm_group_type": "Experimental", 
                "description": "Neural Allo-Transplantation with Fetal Ventral Mesencephalic Tissue"
            }, 
            {
                "arm_group_label": "Control", 
                "arm_group_type": "No Intervention", 
                "description": "comparison group of controls, will receive the same observational and scanning assessments but will not receive any surgical procedures"
            }
        ], 
        "brief_summary": {
            "textblock": "The Transeuro Transplant study is a trial which will involve grafting foetal tissue into the\n      brain of patients with Parkinson's disease, who are already been followed in the\n      observational study. The tissue inserted in the brain is to help replace and rebuild lost\n      dopamine from the brain due to Parkinson's disease. Only 20 patients will be selected for\n      the transplant."
        }, 
        "brief_title": "TRANSEURO Open Label Transplant Study in Parkinson's Disease", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Parkinson's Disease", 
        "condition_browse": {
            "mesh_term": "Parkinson Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must meet ALL of the following criteria to be considered for the enrolment\n             into this study:\n\n               -  PD as defined using Queen's Square Brain Bank criteria.\n\n               -  Disease duration \u2265 2 years and \u2264 11 years.\n\n               -  Aged \u2265 30 years and \u2264 68 years at the time of grafting.\n\n               -  Hoehn & Yahr stage 2.5 or better when 'on'.\n\n               -  On standard anti PD medication without significant LIDs defined as a score of >2\n                  on the AIMS dyskinesia rating scale, in any body part.\n\n               -  Patients must be right handed.\n\n        Exclusion Criteria:\n\n          -  Any of the following will exclude patients from being enrolled in the study:\n\n               -  Atypical or secondary parkinsonism including F-DOPA PET patterns consistent with\n                  this.\n\n               -  Clinically significant response to Levodopa (as evaluated by the clinician)\n                  and/or apomorphine challenge.\n\n               -  Mini-Mental State Examination (MMSE) score of less than 26.\n\n               -  Unable to do normal copying of interlocking pentagons and semantic fluency score\n                  for naming animals of less than 20 over 90 seconds as these have recently been\n                  associated with the earlier onset of dementia in PD.\n\n               -  Ongoing major medical or psychiatric disorder including depression and\n                  psychosis.\n\n               -  Other concomitant treatment with neuroleptics (inc. Atypical neuroleptics) and\n                  cholinesterase inhibitors.\n\n               -  Significant drug induced dyskinesia defined as a score of >2 on the AIMS\n                  dyskinesia rating scale, in any body part.\n\n               -  Previous neurosurgery, cell therapy or organ transplantation.\n\n               -  Unable to be imaged using MRI.\n\n               -  Any contraindication to immunosuppression therapy.\n\n               -  Patients on anticoagulants\n\n               -  Patients who are left handed"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "68 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01898390", 
            "org_study_id": "TRANSEURO", 
            "secondary_id": "FP7-242003"
        }, 
        "intervention": {
            "arm_group_label": "Transplant", 
            "description": "Bilateral Neural Allo-Transplantation with Fetal Ventral Mesencephalic Tissue", 
            "intervention_name": "Transplant", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Parkinson's Disease", 
            "Allo-Transplantation", 
            "Fetal Ventral Mesencephalic Tissue"
        ], 
        "lastchanged_date": "July 11, 2013", 
        "number_of_arms": "2", 
        "official_title": "An Open Label Study to Assess the Safety and Efficacy of Neural Allo-Transplantation With Fetal Ventral Mesencephalic Tissue in Patients With Parkinson's Disease", 
        "other_outcome": [
            {
                "description": "The number of adverse events and serious adverse events associated with the neural transplant", 
                "measure": "AE/SAE's", 
                "safety_issue": "Yes", 
                "time_frame": "0-36 months post treatment"
            }, 
            {
                "description": "Any reported changes in haematology, biochemistry or urinalysis measures outside the normal range", 
                "measure": "Laboratory Parameters", 
                "safety_issue": "Yes", 
                "time_frame": "0-36 months post treatment"
            }, 
            {
                "description": "Vital signs, Physical Exam - new abnormalities will be recorded as an adverse event", 
                "measure": "Other Safety parameters", 
                "safety_issue": "Yes", 
                "time_frame": "0-36 months post treatment"
            }
        ], 
        "overall_official": {
            "affiliation": "Department of Clinical Neurosciences, University of Cambridge", 
            "last_name": "Roger Barker, Prof", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": [
                "United Kingdom: National Health Service", 
                "United Kingdom: Research Ethics Committee"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The change in motor Unified Parkinson's Disease Rating Scale (UPDRS)in a defined \"OFF\" state at 36 months post transplantation. \"OFF\" being defined as receiving no dopamine (DA) therapy for 12 hours prior to assessment or longer in the case of long acting dopamine agonists (e.g. Ropinirole slow release).", 
            "measure": "UPDRS change", 
            "safety_issue": "No", 
            "time_frame": "36 months post transplantation"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01898390"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Cambridge", 
            "investigator_full_name": "Prof Roger Barker", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Change in timed motor tasks at 36 months post transplantation", 
                "measure": "Change in timed motor tasks", 
                "safety_issue": "No", 
                "time_frame": "36 months post transplantation"
            }, 
            {
                "description": "The number of patients with dyskinesias (including L-dopa and graft induced dyskinesias) at 36 months post transplantation", 
                "measure": "Dyskinesias", 
                "safety_issue": "No", 
                "time_frame": "36 months post transplantation"
            }, 
            {
                "description": "L-dopa equivalent medication doses at 36 months post transplantation.", 
                "measure": "L-dopa equivalent medication", 
                "safety_issue": "No", 
                "time_frame": "36 months post transplantation"
            }, 
            {
                "description": "Number of patients on L-dopa therapy at 36 months post transplantation.", 
                "measure": "L-dopa therapy", 
                "safety_issue": "No", 
                "time_frame": "36 months post transplant"
            }, 
            {
                "description": "The amount of 'off' time 36 months post transplantation", 
                "measure": "Off time", 
                "safety_issue": "No", 
                "time_frame": "36 months post transplantation"
            }, 
            {
                "description": "Quality of life (change) 36 months post transplantation", 
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "36 months post transplantation"
            }, 
            {
                "description": "Changes in F-DOPA PET in transplanted patients 36 months post transplantation", 
                "measure": "F-DOPA PET changes", 
                "safety_issue": "No", 
                "time_frame": "36 months post transplantation"
            }
        ], 
        "source": "University of Cambridge", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "University College, London", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Imperial College London", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Cardiff University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Lund University Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University Medical Center Freiburg", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Assistance Publique - H\u00f4pitaux de Paris", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "University of Cambridge", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}